Conditions: Asthma; Allergic Rhinitis; Cystic Fibrosis; Pneumonia
Intervention:
Sponsor: Children’s Hospital Boston
Recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Obstructive Airways Diseases in Pulmonary Clinic (OADPC) Study
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention:
Sponsors: Oridion; Rabin Medical Center
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Hormone drug could cure asthma and other fibrosis-related diseases – Medical Xpress
Medical Xpress |
Hormone drug could cure asthma and other fibrosis-related diseases
Medical Xpress Monash scientists tested the modified Relaxin hormone in animal models of heart failure and asthma. To their surprise they found that administering the new hormone intranasally to animals with chronic allergic airways disease (equivalent to asthma in … |
View full post on asthma – Google News
An estimate of the burden of serious fungal diseases in Greece.
| Related Articles |
An estimate of the burden of serious fungal diseases in Greece.
Eur J Clin Microbiol Infect Dis. 2016 Apr 16;
Authors: Gamaletsou MN, Drogari-Apiranthitou M, Denning DW, Sipsas NV
Abstract
Data on the epidemiology of serious fungal infections in Greece are scarce. Our aim was to calculate the burden of serious fungal diseases in Greece. A thorough literature search for papers reporting epidemiological data on serious fungal diseases in Greece was performed. Where no Greek data existed, we used a structured set of assumptions to estimate fungal disease burden, based on specific high-risk populations. Of the 10.8 million population, 85.5 % are adults and 27 % are over 60 years of age. The annual fungal disease estimates are as follows: 142,337 Greek women get recurrent vaginal thrush (2,632 cases/100,000 females); there are 889 cases of esophageal candidiasis (8.2 cases/100,000); annual incidence of Pneumocystis pneumonia is 112 cases; chronic pulmonary aspergillosis prevalence is 386 cases; there are 20,843 patients with allergic bronchopulmonary aspergillosis and 27,744 with severe asthma with fungal sensitization; candidaemia incidence is 541 cases (5.0/100,000); there are 81 cases of Candida peritonitis; invasive aspergillosis occurs in 1,125 patients. According to our calculations, 194,067 individuals (1.79 cases/100,000) in Greece suffer from serious fungal diseases each year. This is the first attempt to determine the burden of fungal diseases in Greece, and provides a crude estimate on its impact on public health.
PMID: 27086365 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Potential Target for Severe Asthma, Other Chronic Inflammatory Diseases Identified – Lung Disease News
Lung Disease News |
Potential Target for Severe Asthma, Other Chronic Inflammatory Diseases Identified
Lung Disease News From previous research it was known that Dkk-1, a protein produced by platelets (blood cells responsible for clotting), inhibits tissue repair, a feature that is common in chronic inflammatory disorders such as asthma, autoimmune diseases and cancer … |
View full post on asthma – Google News
Study identifies new target for severe asthma, chronic inflammatory diseases – Medical Xpress
Medical Xpress |
Study identifies new target for severe asthma, chronic inflammatory diseases
Medical Xpress Chronic inflammation is commonly found in asthma, autoimmune diseases, cancer, and viral infections, and it's characterized by constant activation of platelets with unhealed tissue damage. Scientists who have studied the Dkk-1 protein were aware that … |
View full post on asthma – Google News
Asthma, COPD and bronchitis: Key differences in common respiratory diseases – Bel Marra Health
Bel Marra Health |
Asthma, COPD and bronchitis: Key differences in common respiratory diseases
Bel Marra Health The differences between asthma and chronic obstructive pulmonary disease, or COPD, are often more clear once risk factors are examined. Risk factors for asthma are different from risk factors for COPD. With asthma the primary risk factors include … The asthma-COPD overlap syndrome: a new entity? |
View full post on asthma – Google News
Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases
Conditions: Chronic Obstructive Pulmonary Disease; Asthma; Overlap Syndrome
Interventions: Drug: LABA + LAMA; Drug: ICS; Drug: LABA + LAMA + ICS; Drug: LABA + ICS; Drug: other
Sponsor: Katholieke Universiteit Leuven
Not yet recruiting – verified June 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.
 |
Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol.
Eur J Intern Med. 2015 Jun 3;
Authors: Santus P, Radovanovic D, Paggiaro P, Papi A, Sanduzzi A, Scichilone N, Braido F
Abstract
Long-acting ?2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low ?2-adrenoceptors availability, like in inflamed airways, a full agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined with the molecule safety profile, leads to a prompt amelioration of the symptoms, and allows using this drug in asthma as an “as needed” treatment in patients already on regular treatment. The fast onset of action and the full agonism of formoterol need to be considered in order to select the best pharmacological treatment of asthma and COPD.
PMID: 26049917 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Valley Medical Group Launches Center for Asthma and Immune Lung Diseases – Patch.com
|
Valley Medical Group Launches Center for Asthma and Immune Lung Diseases
Patch.com Valley Medical Group is proud to announce the opening of the Center for Asthma and Immune Lung Diseases, specializing in the evaluation and treatment of asthma, sarcoidosis, pulmonary fibrosis and immune deficiency disorders. “Our goal at the Center … |
View full post on asthma – Google News